Long-acting oral bromocriptine (Parlodel SRO) in the treatment of hyperprolactinemia
| Autor: | Rita C. Castro, Carlinês R.S. Moraes, Wania Mussio, Cleide O. Weingrill, Evandro Portes, Ana-Maria J. Lengyel |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Male
Ovulation medicine.medical_specialty Radioimmunoassay Administration Oral Gastroenterology Oral administration Internal medicine medicine Humans Short duration Bromocriptine Menstrual Cycle Menstruation Disturbances business.industry Outcome measures Obstetrics and Gynecology Prolactin Hyperprolactinemia Endocrinology Long acting Reproductive Medicine Tolerability Female business medicine.drug |
| Zdroj: | Fertility and sterility. 57(2) |
| ISSN: | 0015-0282 |
| Popis: | Objectives To compare the effect of Parlodel SRO (Sandoz, Basel, Switzerland), a long-acting oral bromocriptine, to Parlodel (Sandoz) and to study the chronic effects of Parlodel SRO. Design The study was twofold: (1) random, double-blind and (2) open. Setting Patients were studied in an academic environment. Patients Hyperprolactinemic patients were selected. Sixteen patients were treated during 1month. Ten patients completed the 1-year follow-up. Interventions Parlodel SRO or Parlodel was administered during 1month (first 15days: 5mg/d; afterwards: 10mg/d). Parlodel SRO was given during 1year in variable doses (maximal 20mg/d). Main Outcome Measures Prolactin (PRL) levels, clinical improvement, and side effects were evaluated. Results After 1month, 63% of the patients in both groups had normal PRL and 43% had menses. Side effects were similar. After 1year all patients except one had normal PRL levels, and 89% were ovulating. Conclusions The efficacy, tolerability, and long duration of action of Parlodel SRO make it an excellent alternative for the treatment of hyperprolactinemic patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|